AN ACT relating to use of experimental treatments for terminal illnesses. Create new sections of KRS Chapter 217 to define terms; permit eligible patients to use investigational drugs, biological products, or devices for a terminal illness; establish the conditions for use of such experimental treatments; prohibit sanctions of health care providers; clarify the duties of health care insurers regarding experimental treatments; prohibit certain actions by state officials.
Bill status
signed
all 3 stages cleared
Introduction
Jan 2017
Committee Review
Mar 2017
Signed into Law
Mar 2017
Introduced Jan 3, 2017
Signed Mar 21, 2017
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
18
Key actions
2
Committee
3
Mar 21, 2017
Signed into law
Signed by Governor (Acts, ch. 65)
legislature
Mar 1, 2017
Legislature · Passed
Posted in committee
legislature
Feb 27, 2017
Committee
To Health and Family Services (H)
legislature
Jan 7, 2017
Committee
To Health & Welfare (S)
legislature
Jan 3, 2017
Introduced
Introduced in Senate
legislature
0 primary · 0 co-sponsors
Sponsors
No sponsor information available.
Ask Maddy
·
AI policy assistant
Ask Maddy about SB 21
Scope: KY
Hi! I can help you understand SB 21. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline